Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Incyte (INCY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sionna Therapeutics, Inc. (SION – Research Report) and Incyte (INCY – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sionna Therapeutics, Inc. (SION)
In a report released today, Yatin Suneja from Guggenheim reiterated a Buy rating on Sionna Therapeutics, Inc., with a price target of $45.00. The company’s shares closed last Monday at $36.82.
According to TipRanks.com, Suneja is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sionna Therapeutics, Inc. with a $47.80 average price target, representing a 32.9% upside. In a report issued on February 2, BTIG also maintained a Buy rating on the stock with a $58.00 price target.
See the top stocks recommended by analysts >>
Incyte (INCY)
In a report released today, Matt Phipps from William Blair maintained a Hold rating on Incyte. The company’s shares closed last Monday at $109.03.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $105.53, a -2.7% downside from current levels. In a report issued on January 29, RBC Capital also maintained a Hold rating on the stock with a $95.00 price target.
